#	Pagina
attuale pagina	/open-h2020/projects/212689/index.html

Opendata, web and dolomites

CureCN SIGNED

Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CureCN project word cloud

Explore the words cloud of the CureCN project. It provides you a very rough idea of what is the project "CureCN" about.

clinical prevent caused broaden rationale threatening label additional marketing aav8 crigler strategies treatments seropositive property re diseases life disease validates glucuronosyltransferase rare clinicians severe itself efficacy mediated burden expressing additionally trial translation immunomodulatory constitutes economic anti irdirc virus transgene vector proposes groundbreaking diphosphate authorization syndrome antibodies multicenter administration gene mutations carry aav recessive liver small ugt1a1 scope bloodstream valorization enterprises ultimately cn issue data technologies proof nabs transfer prove intellectual curecn goals families receiving curative adeno scientists 2020 therapy safety strategy medium removal 1a1 neutralizing uridine file cure selective najjar society treatment disorder patient proportion patients

Project "CureCN" data sheet

The following table provides information about the project.

Coordinator	ASSOCIATION GENETHON Organization address address: RUE DE L INTERNATIONALE 1 BIS city: EVRY postcode: 91002 website: www.genethon.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	https://curecn.eu/
Total cost	6˙249˙103 €
EC max contribution	6˙249˙103 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ASSOCIATION GENETHON ASSOCIATION GENETHON Organization address address: RUE DE L INTERNATIONALE 1 BIS city: EVRY postcode: 91002 website: www.genethon.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (EVRY)	coordinator	3˙738˙478.00
2	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Organization address address: MEIBERGDREEF 15 city: AMSTERDAM postcode: 1105AZ website: www.amc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	526˙718.00
3	EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH Organization address address: HEINRICH-HERTZ-ALLEE 1 city: ST INGBERT postcode: 66386 website: www.eurice.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ST INGBERT)	participant	516˙125.00
4	UNIVERSITY OF LEICESTER UNIVERSITY OF LEICESTER Organization address address: UNIVERSITY ROAD city: LEICESTER postcode: LE1 7RH website: www.le.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LEICESTER)	participant	396˙182.00
5	GENOSAFE SAS GENOSAFE SAS Organization address address: RUE DE L'INTERNATIONALE 1 city: EVRY postcode: 91000 website: www.genosafe.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (EVRY)	participant	207˙017.00
6	ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Organization address address: 3 AVENUE VICTORIA city: PARIS postcode: 75000 website: http://www.aphp.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	172˙083.00
7	MC TOXICOLOGY CONSULTING GMBH MC TOXICOLOGY CONSULTING GMBH Organization address address: SIEBENSTERNGASSE 31/8 city: WIEN postcode: 1070 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	participant	156˙872.00
8	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	149˙000.00
9	AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII Organization address address: PIAZZA OMS 1 city: BERGAMO postcode: 24127 website: www.ospedaliriuniti.bergamo.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BERGAMO)	participant	147˙500.00
10	UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II Organization address address: CORSO UMBERTO I, 40 city: NAPOLI postcode: 80138 website: www.unina.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (NAPOLI)	participant	147˙125.00
11	ASSOCIATION FRANCAISE DE CRIGLER NAJJAR ASSOCIATION FRANCAISE DE CRIGLER NAJJAR Organization address address: 8 RUE HENRI GOLAUDIN city: CLAMART postcode: 92140 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (CLAMART)	participant	92˙000.00

Map

Project objective

Crigler-Najjar syndrome (CN) is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1(UGT1A1) gene. CN is a life-threatening disease with no cure which constitutes a severe burden for the patients, their families, and the society. CureCN has the objective of developing a curative gene therapy for CN syndrome based on liver gene transfer with and adeno-associated virus (AAV) vector expressing the UGT1A1 transgene. Additional goals of CureCN are to develop strategies to allow for vector re-administration and to address the issue of pre-existing anti-AAV neutralizing antibodies (NAbs), which prevent large proportion of seropositive patients from receiving AAV mediated gene therapy. Proof-of-concept studies of AAV8-UGT1A1 gene transfer provide a strong rationale for the safety and efficacy of gene therapy for CN. CureCN proposes to carry out an open-label, multicenter clinical trial of AAV8-UGT1A1 gene transfer to prove the safety and efficacy of the therapy in severe CN patients, and file for marketing authorization in Europe at the end of the study. CureCN will also produce enabling data for the clinical translation of a groundbreaking immunomodulatory strategy to allow for vector administration. Additionally, a technology for the selective removal of anti-AAV NAbs from the bloodstream of seropositive patients will be developed. The goal of these studies is to ultimately allow all CN patients to access AAV8-UGT1A1 gene therapy. CureCN is a patient-driven initiative that gathers top clinicians and scientists; it also includes small medium enterprises in its partners, to foster economic growth and valorization of intellectual property. CureCN sets itself in the ambitious goal set by the IRDiRC by 2020 by developing a curative treatment for CN syndrome. Importantly, it validates technologies that will broaden the scope of gene therapy, thus will have an impact on the development of treatments for several other rare diseases.

Deliverables

List of deliverables.
Public project website	Websites, patent fillings, videos etc.	2020-02-18 10:25:17

Take a look to the deliverables list in detail: detailed list of CureCN deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Fanny Collaud, Giulia Bortolussi, Laurence Guianvarcâ€™h, Sem J. Aronson, Thierry Bordet, Philippe Veron, Severine Charles, Patrice Vidal, Marcelo Simon Sola, Stephanie Rundwasser, Delphine G. Dufour, Florence Lacoste, Cyril Luc, Laetitia v. Wittenberghe, Samia Martin, Christine Le Bec, Piter J. Bosma, Andres F. Muro, Giuseppe Ronzitti, Matthias Hebben, Federico Mingozzi Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome published pages: 157-174, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2018.12.011	Molecular Therapy - Methods & Clinical Development 12	2020-02-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURECN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CURECN" are provided by the European Opendata Portal: CORDIS opendata.